![](https://www.canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBY0E9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--c610b0981f1eff87901f0ef585af6ab1cde7d5af/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Labrys-logo-2.png)
Labrys Biologics
Labrys is developing a monoclonal antibody treatment for the prophylaxis of chronic migraine.
Partner
Wende HuttonInvestment
Series A
Labrys is developing a monoclonal antibody treatment for the prophylaxis of chronic migraine.
Series A